

PharmaMar reports net profit of €5 million at the end of the third quarter of 2018

- **PharmaMar Group's total revenues rose 7% to €133 million in the first nine months of 2018 as compared to the first nine months of 2017**
- **The Group recorded a positive adjusted EBITDA of €2.2 million at the end of September 2018.**

Madrid, 30 of October 2018.- PharmaMar Group (MSE: PHM) reported total revenues of €133 million in the first nine months of 2018. This figure represents an increase of 7% with respect to the same period of the previous year.

Oncology sales in the first nine months of the year totaled €57.4 million, compared to €64.6 million in the same period of 2017. This difference is mainly due to two factors: first, the effect of the sale of Yondelis® raw materials to our partners Janssen Products and Taiho Pharmaceutical, of which €2.5 million were sold in 2017; and second, the erosion of Yondelis® prices in some European countries. Revenue from royalties and licenses and other development agreements totaled €27 million in the first nine months of 2018, compared to €11 million in the same period last year. This increase is due to the recognition in the income statement of €15 million as a result of the early termination of the license agreement of Chugai Pharmaceuticals Co., in 2018. This termination also generated revenues of €3 million.

Sales in the consumer chemicals sector in the first nine months of 2018 were €44.6 million, an increase of 1.7% over the same period last year^(*).

R&D expenditure through the end of the third quarter of 2018 was €57 million, compared to €56.5 million in the first nine months of 2017. In July, PharmaMar reached the target recruitment of 600 patients for the Phase III ATLANTIS trial with Zepsyre® (lurbinectedin) in combination with doxorubicin compared to topotecan or CAV for the treatment of relapsed small-cell lung cancer, the results of which are expected by the end of 2019. Also with regard to lurbinectedin, for the treatment of relapsed small-cell lung cancer, an open label monotherapy phase II trial is being carried out, the preliminary results of which were presented in June 2018 at the ASCO

congress in Chicago. We anticipate target enrolment of 100 being reached this quarter with data reading out in the first half of 2019.

In addition, with regard to Sylentis, the HELIX phase III trial in dry eye disease has recently completed recruitment.

As a result, the Group's adjusted EBITDA for the first nine months of 2018 was €2.2 million compared to € -6.0(*) million in the same period of the previous year and the Group recorded an attributable net profit of €5 million compared to a loss of € -14 million in the same period of the previous year.

*In order to make both periods comparable, the results to September 2017 have been adjusted taking into account the discontinued operation due to the sale of Xylazel announced on September 20, 2018.

Legal warning

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

About PharmaMar

Headquartered in Madrid, PharmaMar is a biopharmaceutical company, focused on oncology and committed to research and development which takes its inspiration from the sea to discover molecules with antitumor activity. It is a company that seeks innovative products to provide healthcare professionals with new tools to treat cancer. Its commitment to patients and to research has made it one of the world leaders in the discovery of antitumor drugs of marine origin.

PharmaMar has a pipeline of drug candidates and a robust R&D oncology program. It develops and commercializes Yondelis® in Europe and has other clinical-stage programs under development for several ty-pes of solid cancers: lurbinectedin (PM1183), PM184 and PM14. With subsidiaries in Germany, Italy, France, Switzerland, Belgium, Austria and the United States. PharmaMar wholly owns other companies: GENOMICA, a molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and a chemical enterprise, Zelnova Zeltia. To learn more about PharmaMar, please visit us at www.pharmamar.com

Media Contact:

Alfonso Ortín – Communications Director aortin@pharmamar.com Mobile: +34 609493127
Miguel Martínez-Cava – Digital Communication Manager mmartinez-cava@pharmamar.com Mobile: +34 606597464
Phone: +34 918466000





Investor Relations:

Phone: +34 914444500

Or please visit our website at www.pharmamar.com